New research published today in Science Translational Medicine reveals a potential breakthrough into the cause of this disease, and also provides a possible treatment lead. Led by HSS researcher Dr. Franck Barrat—the Michael Bloomberg Chair and Senior Scientist at HSS - along with clinicians of the Scleroderma center of HSS, the work implicates what are called plasmacytoid dendritic cells (pDCs) in contributing to scleroderma.
Wednesday, January 17, 2018
New study finds hope in understanding and better treating scleroderma.
1/17/2018 05:47:00 PM
No comments
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment